Product Name: Flt3 (35-50)
Product Number: PE-01AUJ95
Size: 200 µg      Price:51.00
1 mg      $US102.00
5 mg      224.00
Peptide Name: Flt3 (35-50)

Product Use: Services as a blocking peptide for use with the Flt3-1 rabbit polyclonal antibody (Cat. No.: AB-NK240-1) that is also available from Kinexus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CVLINHKNNDSSVGKS

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1713.9 Da

Peptide Purity Percent after Synthesis and Purification: 95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Flt3 pan-specific antibody (Cat. No.: AB-NK240-1)

Scientific Background: Flt3 (FLK2) is a protein-tyrosine kinase of the TK group and PDGFR family. It is involved in cell proliferation, differentiation and survival through the binding of its ligand, Flt3LG. Autophosphorylation of Y591 increases phosphotransferase activity. Autophosphorylation of Y599 increases phosphotransferase activity and induces interaction with SHP2 and Src. Flt3 will induce phosphorylation of Shc1 and Akt1 leading to a change in the downstream regulator mTOR. It can activate the Ras signalling pathway and lead to phosphorylation of downstream kinases such as MAPK1/ERK2 and MAPK3/ERK1. Mutations causing constitutive activity promote cell proliferation and resistance to apoptosis. Defects have been associated with acute myelogenous leukemiaFlt3 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Flt3 is linked with Acute Myeloid Leukemia (AML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndromes (MSD), Acute Promyelocytic Leukemia, Myeloid Sarcoma, Chronic Myeloproliferative Disease (CMPD), Acute Biphenotypic Leukemia (BAL), Precursor T-Cell Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic 3 (B-ALL), Acute Myeloblastic Leukemia with Maturation, Minimally Differentiated Acute Myeloblastic Leukemia is a subtype of AML, and Gastrointestinal Stromal tumour (GANT). STAT5A activation involves Y589 and Y591 phosphorylation. A Y599F mutation can interrupt Flt3 complex formation with PTPN11/SHP2.